Ipamorelin

Vialdyne primary owner

Overview

Ipamorelin is a five-residue pentapeptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, designed for sharp selectivity at the GHSR (ghrelin / growth-hormone secretagogue receptor). The structural feature that distinguishes it from the older and broader GHRP family (GHRP-2, GHRP-6, Hexarelin) is exactly that selectivity envelope: Ipamorelin engages GHSR while sparing the related receptors that drive cortisol, prolactin, and ACTH release. The absence of cortisol-axis activation is what makes the molecule the cleanest GH-selective option for routine 503A compounding workflows and for any research context where secondary-axis effects would contaminate the readout. For compounding pharmacy buyers, Vialdyne releases Ipamorelin acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The 5-residue sequence is straightforward by SPPS, so the standard batch packet centres on peak-integration RP-HPLC plus ESI-MS identity; LC-MS/MS sequence verification is available on request but is rarely the load-bearing test for a pentapeptide. Most catalogue volume is paired with a GHRH-class agonist (CJC-1295 no-DAC, Sermorelin, or Tesamorelin) in dual-pathway preparations. The canonical CJC-1295 + Ipamorelin pairing is supplied directly as a pre-blended co-lyophilised vial under the cjc-1295-ipamorelin SKU at the standard 5+5 mg fill, with non-standard ratios scoped under change-control. The companion [CJC-1295 + Ipamorelin pharmacology article](/insights/cjc-1295-ipamorelin-blend-pharmacology-guide) covers the dual-pathway rationale and the ratio considerations.

Applications & buyer fit

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.

Specifications

CAS

170851-70-4

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

2 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 2 hours

MOQ

On request

Lead time

7–14 days

Storage

2–8°C, protect from light

Certificate of Analysis

Representative COA previews for Ipamorelin; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Ipamorelin

VD260428-IPA10116 · 99.53%

VerifiedRequest full COA →

Ipamorelin

VD260428-IPA114 · 99.40%

VerifiedRequest full COA →

Ipamorelin

VD260428-IPA5115 · 99.45%

Regulatory note

Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.

Selected literature

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
2. Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113.
3. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577.
4. Svensson J, Lönn L, Jansson JO, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(3):163-170.
5. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416.
6. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116.

Frequently asked questions